Professor Jane Armitage
|Tel||+44 (0)1865 743743|
- ASCEND: A Study of Cardiovascular Events iN Diabetes Research Group
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D Research Group
- HPS: Heart Protection Study Research Group
- HPS2 -THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events Research Group
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Research Group
- CTT: Cholesterol Treatment Trialists' Collaboration Research Group
- Trials Methodology Research Group
- Research Regulation Research Group
- Oxford Cholesterol Study Research Group
- LENS: Lowering Events in Non-proliferative retinopathy in Scotland Research Group
Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
- MRC PHRU Programme Leader
Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine. In addition, she is Director of Training and Career Development for the Nuffield Department of Population Health.
She joined the Clinical Trial Service Unit, now part of NDPH, in 1990 having qualified in clinical medicine in 1979. She worked in a variety of specialties over several years with particular experience in respiratory medicine, geriatrics and diabetes. Since joining CTSU she has co-ordinated and been chief investigator for a series of large-scale randomised clinical trials in cardiovascular disease including the 20,000 participant MRC/BHF Heart Protection Study, the 12,000 patient SEARCH and 25,000 HPS2-THRIVE study, which are trials of lipid modification in people with or at risk of vascular disease. In addition she is Chief Investigator for the BHF-supported ASCEND trial of aspirin and fish oils involving 15,000 people diabetes. She collaborates with other epidemiologists and statisticians in NDPH on a variety of genetic and other risk factor studies based on the trial cohorts. She also continues a clinical role in the Lipid Clinic at the Oxford University Hospital NHS Trust and has a particular interest in the safety of statins. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic diseases including osteoporosis.
Effects of extended-release niacin with laropiprant in high-risk patients.
HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494
The safety of statins in clinical practice.
Armitage J., (2007), Lancet, 370, 1781 - 1790
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R. et al, (2016), Lancet
Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease.
Herrington W. et al, (2016), Circ Res, 118, 535 - 546
Management of residual risk after statin therapy.
Reith C. and Armitage J., (2016), Atherosclerosis, 245, 161 - 170
Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
Aung T. et al, (2016), Trials, 17
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
Kitas GD. et al, (2015), ARTHRITIS & RHEUMATOLOGY, 67